Durable, ongoing near-complete response to nivolimab + relatlimab in a 64-year-old with locally-advanced BCC after resistance to 26 weeks of nivolimab alone. Photo by: Evan Lipson, M.D. A new study led by researchers at the Johns Hopkins Kimmel Cancer Center found that patients with advanced basal cell carcinoma (BCC) may benefit from receiving immunotherapy earlier in treatment. Results from the phase 2 clinical trial (NCT03521830), presented Oct. 20 at the European Society

New findings suggest the development of cutaneous immune-related adverse events (cirAEs) is associated with better treatment efficacy and...